COMPASS Pathways
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | - | 25.2m |
| EBITDA | (32.2m) | (68.7m) | (88.0m) | (108m) | (152m) | (160m) | (183m) |
| % EBITDA margin | - | - | - | - | - | - | (724 %) |
| Profit | (54.8m) | (65.2m) | (83.2m) | (108m) | (140m) | (161m) | (177m) |
| % profit margin | - | - | - | - | - | - | (703 %) |
| EV / revenue | - | - | - | - | - | - | 12.9x |
| EV / EBITDA | -42.9x | -8.6x | -2.0x | -2.9x | -1.9x | -2.3x | -1.8x |
| R&D budget | 21.2m | 40.0m | 59.1m | 79.6m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | £3.0m | Seed | |
* | $25.0m | Series A | |
N/A | Convertible | ||
* | $80.0m | Series B | |
| N/A | $128m Valuation: $544m -29.6x EV/LTM EBITDA | IPO | |
* | $30.0m | Post IPO Debt | |
* | $285m | Private Placement VC | |
| Total Funding | €358m | ||
Related Content
Recent News about COMPASS Pathways
EditCOMPASS Pathways plc is a mental health care company focused on developing innovative treatments for mental health disorders, specifically targeting treatment-resistant depression. The company operates in the pharmaceutical and biotechnology market, leveraging its proprietary psilocybin therapy, COMP360, to address unmet medical needs. COMPASS Pathways serves patients who have not responded to traditional antidepressant therapies, providing a novel approach through its clinical trials and research initiatives. The business model is centered around the development, clinical testing, and eventual commercialization of its psilocybin-based treatments. Revenue is generated through partnerships, licensing agreements, and future sales of approved therapies. The company has gained significant attention and investment, highlighted by its successful $146.6 million IPO and participation in major industry conferences.
Keywords: psilocybin therapy, mental health, treatment-resistant depression, clinical trials, biotechnology, pharmaceutical, COMP360, innovative treatments, IPO, research initiatives.